About Us

Your reliable partner for AAV Development, Validation and Manufacturing

01About us

Who we are

Viralgen Vector Core becomes the convergence point from experienced specialized organizations in biotechnology and life science fields, united with the aim of creating a CDMO in the sector of gene therapy and innovative medicines. Developing and manufacturing in order to contribute to the progress in health and welfare of people.

One of the key aspects for this exclusive technology to reach patients is the cGMP production for rAAV manufacturing in large batches. Askbio has been working in the field of gene therapy for more than 15 years and has developed its own cell line and manufacturing system. This allows large cGMP manufacturing of rAAV vectors with superior yield to others in the market.

Javier García DamiàTormo Jude Samulski PhD Sheila Mikhail Background JointVenture

02About AskBio

Asklepios BioPharmaceutical, Inc. (AskBio) was founded in 2003 by Richard Jude Samulski, PhD, and Sheila Mikhail in Chapel Hill, North Carolina to take advantage of the deep gene therapy resources in the Research Triangle Park area. AskBio has since set the standard for gene therapy clinical development including a deep portfolio of intellectual property in gene therapy for multiple disease and an advanced manufacturing process.

AskBio has established and formed industry alliances for multiple spin out companies and continues to pursue new gene therapy technologies and treatments. Among those spin out are NanoCor Therapeutics (partnered with Medtronics to develop treatment for heart failure), Chatham Therapeutics (sold to Baxter to develop hemophilia treatments), and Bamboo Therapeutics (sold to Pfizer to develop cures for rare neuromuscular diseases and muscular dystrophy).

03About Columbus Venture Partners

Columbus Venture Partners is a Spanish investment Management Company with an investment strategy focused on the early-stage and high growth opportunities of biotechnology, medical technology, pharmaceuticals and healthcare industries in Spain. Its team of professionals combines a solid scientific, medical and business knowledge with an extensive experience in the establishment and investment of companies to accelerate merchandising.

The Columbus investment team has more than 75 years of professional experience with venture capital investments in pharmaceutical and biotechnology companies and invests through the COLUMBUS INNVIERTE Life Science Fund, FCR.

04Management

Javier García Cogorro

Chief Executive Officer

Has spent almost 30 years working in healthcare and the biopharmaceutical industry and has focused on life science venture capital investing since 2009, where he focuses on private company investments in the biopharmaceutical, life science and medical technology sectors. Mr. García received a Bachelor in Mathematics (Statistics and Operations Research) from Universidad Complutense of Madrid and a MBA from ICADE (Spain).

César Trigueros

Chief Scientific Officer

Doctor in Molecular Biology. Over 20 years of leadership experience in the field of biotechnology with special interest in gene therapy and immunology in both industry and academic settings.

Philippe Moullier

MD, PhD is Chief Scientific Officer Europe of Asklepios Biopharmaceutical (AskBio)

Inc since May 2017 after working as collaborator of Bamboo Therapeutics from March 2015 through July 2016. Philippe Moullier was the founder and until Dec 2016, the Director of the research INSERM Unit UMR 1089 entitled « Translational Gene Therapy for Retinal and Neuromuscular Diseases » at the University of Nantes, France. In January 2018, Philippe Moullier has been appointed Chief Development Officer at ViralGen VC in San Sebastian, Spain in the context of the partnership with AskBio. His dual appointments allows the reinforcement of the US-Spanish strategic partnership.

Andy Holt

Vice President, Business Development

Comes to Viralgen with more than a decade in biotech business development across the contract testing and manufacturing industries. He has worked with AAV companies bringing therapies to the clinic and market since 2008 and remains as passionate and awestruck about the power of this technolgy as he was when he first had a chance to be a part of it. A native of Atlanta, Georgia,he holds a BSc in Applied Biology from Georgia Tech and calls Raleigh North Carolina home.

05Past clients and clinical trial preps using Pro10™

Canavan disease UMDNJ
2003 | Canavan disease UMDNJ
DMD Children’s Hospital Ohio
2006 | DMD Children’s Hospital Ohio
Retinal neovascularization U of western Australia
2011 | Retinal neovascularization U of western Australia
Current: Hemophilia Multiple Sites
2013 | Current: Hemophilia Multiple Sites